Pulmonary Embolism Market Size to Reach USD 4.78 Billion by 2034
The global pulmonary embolism market size is calculated at USD 2.15 billion in 2024, grows to USD 2.33 billion in 2025, and is projected to reach around USD 4.78 billion by 2034, and is expected to undergo a CAGR of 8.32% during the forecast period 2025-2034. The expansion of the pulmonary embolism market can be linked to the rising cases of venous thromboembolism (VTE), expanding healthcare infrastructure and ongoing advancements in treatment modalities.
Pulmonary embolism (PE) refers to blockage of an artery in lungs due to blood clot formation, preventing blood flow and further may lead to serious and life-threatening complications that require immediate medical assistance. Various chronic conditions such as cancer and cardiovascular diseases as well as lifestyle factors such as smoking obesity and long-term immobility are likely increase risk of blood clots which can lead to PE. Rising healthcare expenditure across the globe, increased number of clinical trials, technological innovations, increased awareness, focus on addressing unmet needs and demand for personalized treatments are the factors driving the growth of the pulmonary embolism market.
Artificial intelligence (AI) algorithms can be applied for analyzing CT pulmonary angiograms (CTPA) and other types of medical images for identification of early signs of pulmonary embolism (PE). Based on clinical data of patients, AI can assist in evaluating patients at high risk of developing PE and requiring a rigorous treatment. AI-powered models can aid in clinical decision support by providing insights on the size, location and other features of the emboli, further enabling better treatment decisions. Personalization of treatment strategies can be achieved with the integration of AI. Optimization of treatments, risk stratification and enhanced workflow efficiency reducing turnaround times for radiologists with the incorporation of AI is reducing mortality rates related to PE and improving patient outcomes.
| Report Coverage | Details |
| Market Size in 2025 | USD 2.33 Billion |
| Market Size by 2034 | USD 4.78 Billion |
| Growth Rate From 2025 to 2034 | CAGR of 8.32% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | By Symptoms, By Diagnosis, By Treatment, By End-Users, By Distribution Channel, By Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | Abbott, Aspen Holdings, AstraZeneca, Baxter, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Genentech Inc., Glaxo Smith Kline plc, Hikma Pharmaceuticals PLC, Johnson & Johnson Private Limited, Merck & Co., Inc., Mylan N.V., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd. |
Drivers
Rising Cases of Blood Clots
Globally shifting demographics towards an aging population and rising incidences of chronic diseases are leading to development of blood clots which results in deep vein thrombosis and pulmonary embolism. Moreover, factors such as sedentary lifestyles, smoking and dietary habits, hormone replacement therapy, and connective tissue conditions like rheumatoid arthritis and lupus are other major causes of pulmonary embolism driving the need for effective treatments.
Diagnostic Hurdles
Symptoms of PE such as chest pain, cough and shortness of breath are generally imprecise and also overlap with other conditions like anxiety, heart failure, pneumonia which can make it for clinicians for accurately suspecting or identifying PE, leading to delayed diagnosis or medical error. Non-specific nature of PE symptoms and limitations of diagnostics tools can significantly impact the market growth.
Continuous Advancements in Treatment Options
Manufacturers and researchers are focused on developing novel and enhanced treatments such as ultrasound-assisted catheter-directed thrombolysis (USCDT), targeted therapies, genomic and personalized medicine, vena cava filters, compression stockings and next-generation anticoagulants. These innovative technologies and therapies are helping improve patient outcomes, further creating opportunities for market growth.
What Drives the Dominance of the Shortness of Breath Segment?
By symptoms, shortness of breath segment dominated the market in 2024. Shortness of breath or dyspnea is a common and primary symptom of pulmonary embolism which is observed in aging demographics and people with conditions such as cancer, diabetes and heart disease. Moreover, surge in obesity rates, sedentary lifestyles, rising surgical procedures as well as increased estrogen levels due to hormone replacement therapy or consumption of oral contraceptives is leading to increased cases of PE creating the need for effective treatments. Advancements in diagnostic technologies, development of targeted therapies, personalized medicine approaches and increased awareness promoting early detection are the factors driving the market dominance of this segment.
By symptoms, irregular heartbeat segment is expected to register the fastest CAGR during the forecast period. Arrhythmias or irregular heartbeats are increasingly being screened in patients with increasing awareness of association of heart rhythm abnormalities with PE, leading to rise in patients seeking early diagnosis and treatments. Adoption of advanced treatment options such as novel oral anticoagulants (NOACs), interventional therapies like catheter-directed thrombolysis and mechanical thrombectomy, surgical embolectomy, and supportive measures such as oxygen therapy and hemodynamic support are enabling better management and improved patient outcomes.
Why Did CT Scan Segment Dominate in 2024?
By diagnosis, the CT scan segment accounted for the largest market share in 2024. Direct visualization of blood clots in pulmonary arteries with high accuracy and speed as well as widespread availability in hospitals and emergency departments makes CT scan as the most frequently used diagnostic technology for PE. CTPA (CT pulmonary angiography) is considered as the golden standard for diagnosing PE and widely accepted among patients due to its non-invasive nature. Advancements in Computed Tomography (CT) technology such as multi-detector CT (MDCT) facilitating better detection of small and subsegmental pulmonary emboli, dual-energy CT (DECT) offering functional and morphological information in a single scan as well as use of sophisticated software for detailed 3D reconstruction of images is creating opportunities for market growth.
By diagnosis, the D-dimer test segment is anticipated to witness lucrative growth over the forecast period. Rising prevalence of venous thromboembolism (VTE) cases which includes deep vein thrombosis (DVT) and PE is driving the adoption of point-of-care D-dimer tests which offer a quick and convenient way for detecting PE. Cost-effective and non-invasive nature of these tests is leading to increased patient adherence, compliance and use in various healthcare settings. Integration of D-dimer testing kits with multi-marker panels are enabling wider assessment of conditions such as cardiac ailments or sepsis, further facilitating development of personalized treatment approaches.
What Made Medications the Dominant Segment in 2024?
By treatment, medications segment held the largest market share in 2024. Continuous advancements in drug formulations and delivery systems have led to the development of novel oral anticoagulants such as apixaban, dabigatran, edoxaban and rivaroxaban which are transforming PE treatment through their various benefits such as convenience oral administration, rapid onset of action, fixed dosage regimens, lesser drug-drug interactions and improved safety profiles. Pharmaceutical companies are heavily investing in research and clinical trials for development of more effective and safe thrombolytic therapies.
By treatment, the mechanical devices segment is expected to show the fastest growth during the predicted timeframe. Increased prevalence of pulmonary embolism and rising demand for minimally invasive procedures over traditional surgical approaches is creating the demand for mechanical thrombectomy. Growing market penetration of innovative technologies such as novel aspiration systems, stent retrievers and other type of specially designed thrombectomy catheters are facilitating quick and efficient clot removal. Real world evidence with positive outcomes from clinical studies is driving the adoption of mechanical thrombectomy.
How Hospital Pharmacy Segment Dominated the Market in 2024?
By distribution channel, the hospital pharmacy segment generated the highest market revenue in 2024. Hospital pharmacies play a crucial role in management and dispensing of wide range of PE treatment medications such as different anticoagulants, reversal agents and drugs for supportive care. Pharmacists in hospitals provide dosing and monitoring expertise as well as follow strict protocols for ensuring safe and effective use of PE medications and addressing adverse drug events. Globally rising investments in advancing healthcare infrastructure and improving access to healthcare systems is driving the market expansion of this segment.
By distribution channel, the online pharmacy segment is expected to expand rapidly over the forecast period. Online pharmacies offer a convenient and accessible option with the benefit of ordering PE medications from the comfort of home, especially for people living in remote areas and limited mobility. Competitive pricing and discounts offered by online pharmacies over traditional retail pharmacies is attracting consumers with tight budget. Increased penetration of digital technologies in the healthcare and pharmaceutical sectors is enabling access to telepharmacy services, e-prescribing software and digital health applications.
Why Did the Hospitals Segment Generate Highest Revenue in the Market in 2024?
By end-users, the hospitals segment accounted for the largest market share in 2024. Hospitals are equipped with the necessary medical facilities, diagnostic technologies and equipment for the diagnosis and management of pulmonary embolism. Multidisciplinary teams of healthcare professionals such as pulmonologists, radiologists, cardiology and emergency medicine specialist in hospitals facilitate establishment of Pulmonary Embolism Response Teams (PERT Teams) which can optimize decision-making in complex PE cases, further providing timely access to advanced treatments.
By end-users, the homecare segment is expected to show the fastest growth during the forecast period. Shifting patient preference towards home healthcare to reduce medical expenses and psychological burden of hospitalization as well as continuous advancements in treatment and improvements in PE management protocols leading to reduced hospital stays is driving the market growth of this segment. Emergence of telemedicine platforms and availability of remote monitoring tools are enhancing home-based care for patients and enabling remote consultations with healthcare professionals.
What Drives North America’s Dominance in the Pulmonary Embolism Market?
North America dominated the global pulmonary embolism market with the largest share in 2024. Increasing prevalence and risk factors associated with PE, advanced healthcare facilities, growing awareness among healthcare professionals and the population, robust research infrastructure and strong presence of key market players are the factors driving the market dominance of this region. Additionally, stringent regulations, supportive reimbursement policies and access to advanced diagnostic procedures are bolstering the market growth.
How is Asia Pacific Approaching the Pulmonary Embolism Market?
Asia Pacific is expected to show the fastest growth in the global market over the forecast period. The region’s large and aging population with rising burden of cardiovascular diseases and cancer is creating the need for effective pulmonary embolism treatments. Increased healthcare expenditure, burgeoning pharmaceutical sector in India and China, favorable government policies, adoption of advanced medical technologies and rising demand for minimally invasive procedures are the fueling the market growth of this region.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the Pulmonary Embolism Market
By Symptoms
By Diagnosis
By Treatment
By End-Users
By Distribution Channel
By Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers